In focus · trending topic

tucatinib regulatory update

2 stories · following the connections

Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer

By Nasdaq OMXSep 27, 2017, 11:00 AM UTC

Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe

By Nasdaq OMXJul 11, 2017, 12:01 PM UTC